Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Bifulco

Showing results (111-120 of 210) with videos related to

Pageof 21
Sort By:
Journal of Cosmetic Dermatology|July 13, 2022
The medieval skincare routine according to the formulations of Madgistra Trotula and the Medical School of Salerno and its reflection on cosmetology of the third millenniumSimona Pisanti, Teresa Mencherini, Tiziana Esposito, et al.
Endocrine|November 21, 2020
The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are neededMaurizio Bifulco, Michele Ciccarelli, Dario Bruzzese, et al.
International Journal of Molecular Sciences|November 13, 2021
PRDM12 in Health and DiseasesMonica Rienzo, Erika Di Zazzo, Amelia Casamassimi, et al.
Molecular Pharmacology|July 11, 2006
The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanismDaniela Sarnataro, Simona Pisanti, Antonietta Santoro, et al.
Pharmacological Research|November 30, 2011
The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in miceAnna Maria Malfitano, Chiara Laezza, Mario Galgani, et al.
Scandinavian Journal of Gastroenterology|October 22, 2008
Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell linesMaria Notarnicola, Caterina Messa, Antonella Orlando, et al.
Anti-Cancer Agents in Medicinal Chemistry|February 22, 2008
Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drugMaurizio Bifulco, Anna Maria Malfitano, Maria Chiara Proto, et al.
The FEBS Journal|October 12, 2013
N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin AMaurizio Bifulco, Alba D'Alessandro, Simona Paladino, et al.
Molecular Aspects of Medicine|November 30, 2020
Immunometabolism of regulatory T cells in cancerMario Galgani, Sara Bruzzaniti, Claudia La Rocca, et al.
Journal of Cellular Physiology|June 4, 2009
A new role of anandamide in human sperm: focus on metabolismSaveria Aquila, Carmela Guido, Chiara Laezza, et al.
Pageof 21

Showing results (111-120 of 210) with videos related to

Sort By:
Pageof 21
Journal of Cosmetic Dermatology|July 13, 2022
The medieval skincare routine according to the formulations of Madgistra Trotula and the Medical School of Salerno and its reflection on cosmetology of the third millenniumSimona Pisanti, Teresa Mencherini, Tiziana Esposito, et al.
Endocrine|November 21, 2020
The benefit of statins in SARS-CoV-2 patients: further metabolic and prospective clinical studies are neededMaurizio Bifulco, Michele Ciccarelli, Dario Bruzzese, et al.
International Journal of Molecular Sciences|November 13, 2021
PRDM12 in Health and DiseasesMonica Rienzo, Erika Di Zazzo, Amelia Casamassimi, et al.
Molecular Pharmacology|July 11, 2006
The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanismDaniela Sarnataro, Simona Pisanti, Antonietta Santoro, et al.
Pharmacological Research|November 30, 2011
The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in miceAnna Maria Malfitano, Chiara Laezza, Mario Galgani, et al.
Scandinavian Journal of Gastroenterology|October 22, 2008
Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell linesMaria Notarnicola, Caterina Messa, Antonella Orlando, et al.
Anti-Cancer Agents in Medicinal Chemistry|February 22, 2008
Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drugMaurizio Bifulco, Anna Maria Malfitano, Maria Chiara Proto, et al.
The FEBS Journal|October 12, 2013
N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin AMaurizio Bifulco, Alba D'Alessandro, Simona Paladino, et al.
Molecular Aspects of Medicine|November 30, 2020
Immunometabolism of regulatory T cells in cancerMario Galgani, Sara Bruzzaniti, Claudia La Rocca, et al.
Journal of Cellular Physiology|June 4, 2009
A new role of anandamide in human sperm: focus on metabolismSaveria Aquila, Carmela Guido, Chiara Laezza, et al.
Pageof 21